The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells

Experimental Hematology

Volumn 30, Issue 7, 2002, Pages 767-773

  Spiekermann, Karsten ^a   Faber, Florian ^a   Voswinckel, Robert ^b   Hiddemann, Wolfgang ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SU 1498; SU 5614; TYROSINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS;

ACUTE DISEASE; ANIMALS; APOPTOSIS; AUTOCRINE COMMUNICATION; CELL DIVISION; CULTURE MEDIA, SERUM-FREE; DRUG RESISTANCE; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; GROWTH INHIBITORS; HEMATOPOIETIC STEM CELLS; HUMANS; INDOLES; LEUKEMIA, MYELOID; LYMPHOKINES; MICE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036325621     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)00837-8     Document Type: Article

References (34)

1. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
2. Angiogenesis and tumor metastasis
3. High-affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
4. The biology of vascular endothelial growth factor
5. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature
6. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
7. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
8. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PlGF) in regulating human haemopoietic cell growth
9. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
10. Increased bone marrow vascularization in patients with acute myeloid leukaemia: A possible role for vascular endothelial growth factor
11. Evidence of increased angiogenesis in patients with acute myeloid leukemia
12. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
13. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation
14. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor
15. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias
16. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
17. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
18. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
19. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
20. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases
21. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins and is sufficient to transform hematopoietic precursor cells
22. De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop
23. Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: Heterogeneity in response and synergy with other hematopoietic growth factors
24. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
25. TGF-β inhibits growth and induces apoptosis in leukemic B cell precursors
26. A novel, microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis
27. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases
28. Cancer treatment in the STI571 era: What will change?
29. Flk-1 as a target for tumor growth inhibition
30. C-kit mutations in core binding factor leukemias
31. C-kit and c-kit mutations in mastocytosis and other hematological diseases
32. Expression of the stem cell factor receptor c-kit (CD117) in acute leukemias
33. Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias
34. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification